DeutschNewstral
Article
Mmarketwatch.com on 2019-02-01 22:58
Alkermes shares fall after FDA blocks antidepressant approval
Related news
- MBiogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surgesmarketwatch.com
A ketamine-like drug is the first new antidepressant to get FDA approval in decadesvox.com- MAlnylam shares jump on FDA approvalmarketwatch.com
- MAquestive shares jump on FDA approvalmarketwatch.com
- FSarepta shares surge 90% on FDA approvalft.com
White House blocks tougher FDA guidelines on vaccine approvalKING 5
FDA rejects Alkermes' depression drug, questions effectivenessbizjournals.com- MZogenix's shares rise on FDA approval of seizure drugmarketwatch.com
- Teva shares down 13% following FDA approval of generic Copaxonebizjournals.com
- MVertex shares up more than 1% after FDA drug approvalmarketwatch.com
- MAmicus shares drop 28% after FDA denies quick drug approvalmarketwatch.com
- MAbiomed gets heart-pump FDA approval, shares haltedmarketwatch.com
- MEyePoint Pharma shares jump on FDA approval of Yutiq implantmarketwatch.com
- MAlkermes stock falls after FDA committee votes against depression drugmarketwatch.com
- MAlkermes shares rise on schizophrenia drug approvalmarketwatch.com
- Alkermes blames drug rejection on Covid halting FDA inspectionsbizjournals.com
- The Petri Dish: Alkermes, Foundation Medicine see FDA approvalsbizjournals.com
- MFDA told Alkermes to stop publishing Vivitrol admarketwatch.com